Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes
Study Details
Study Description
Brief Summary
This is a 28-week extension to a study of the safety and effectiveness of three doses of vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose levels in people with type 2 diabetes who have not been previously treated with drug therapy to lower their blood sugar. The purpose of the extension study is to gather long-term safety and efficacy data for vildagliptin in people with type 2 diabetes.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 3 |
Study Design
Outcome Measures
Primary Outcome Measures
- Safety of vildagliptin during 52 weeks of treatment []
- Change from baseline in HbA1c at 52 weeks []
Secondary Outcome Measures
- Change in HbA1c between 24 weeks and 52 weeks []
- Change from baseline in fasting plasma glucose at 52 weeks []
- Change in fasting plasma glucose between 24 weeks and 52 weeks []
- Change from baseline in HOMA B at 52 weeks []
- Change from baseline in HOMA IR at 52 weeks []
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Only patients successfully completing study CLAF237A2301 are eligible
-
Written informed consent
-
Ability to comply with all study requirements
Exclusion Criteria:
-
Premature discontinuation from study CLAF237A2301
-
Other protocol-defined exclusion criteria may apply
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Novartis Pharmaceuticals | East Hanover | New Jersey | United States | 07936 |
Sponsors and Collaborators
- Novartis
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CLAF237A2301E1